Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Acute Kidney Injury | Commentary

Indoxyl sulfate is associated with mortality after AKI – more evidence needed!

Authors: Steven Menez, Mohamad Hanouneh, Tariq Shafi, Bernard G. Jaar

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Patients who develop acute kidney injury (AKI) have significantly higher short-term outcomes including in-hospital mortality. The development of AKI has been associated with long-term consequences including progression to chronic kidney disease (CKD) and higher rates of cardiovascular disease (CVD) and mortality. In recent years there has been a growing push for the discovery of novel methods to diagnose AKI at earlier stages, and for an improvement in risk stratification and prognosis following AKI.
Wang and colleagues assessed the association of total serum indoxyl sulfate (IS) levels, a protein bound uremic toxin, with 90-day mortality after hospital-acquired AKI (HA-AKI). These authors found that serum IS levels were significantly elevated in patients with HA-AKI (2.74 ± 0.75 μg/mL) compared to healthy subjects (1.73 ± 0.11 μg/ml, P < 0.001) and critically ill patients (2.46 ± 0.35 μg/ml, P = 0.016).
The mechanisms of this relationship remain unclear, with a limited understanding of cause-specific mortality associated with either the high or low-IS group. One limitation of this current study is an understanding of the acceptable or expected higher level in IS during episodes of AKI. IS levels remained persistently elevated at day 7 compared to β2-microglobulin and serum creatinine which were both lower at 7 days. It is unclear, however, if levels of β2-microglobulin and serum creatinine were lower for other reasons, such as if any patients with AKI required dialysis.
This work provides an important addition to the field of AKI research, specifically in the evaluation of readily measurable biomarkers and outcomes after AKI. Moving forward, further validation in studies of acute kidney injury are needed to develop a better understanding of IS levels at the time of AKI diagnosis and trends during the course of AKI.
Literature
1.
go back to reference Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–70.PubMedCrossRef Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–70.PubMedCrossRef
2.
go back to reference Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL. Acute kidney injury advisory Group of the American Society of N: world incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8(9):1482–93.PubMedPubMedCentralCrossRef Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL. Acute kidney injury advisory Group of the American Society of N: world incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8(9):1482–93.PubMedPubMedCentralCrossRef
3.
go back to reference Negi S, Koreeda D, Kobayashi S, Yano T, Tatsuta K, Mima T, Shigematsu T, Ohya M. Acute kidney injury: epidemiology, outcomes, complications, and therapeutic strategies. Semin Dial. 2018;31(5):519–27.PubMedCrossRef Negi S, Koreeda D, Kobayashi S, Yano T, Tatsuta K, Mima T, Shigematsu T, Ohya M. Acute kidney injury: epidemiology, outcomes, complications, and therapeutic strategies. Semin Dial. 2018;31(5):519–27.PubMedCrossRef
4.
5.
go back to reference Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Prac. 2013;2013:479730. Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Prac. 2013;2013:479730.
6.
go back to reference Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int. 2012;81(9):819–25.PubMedCrossRef Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int. 2012;81(9):819–25.PubMedCrossRef
7.
go back to reference Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol. 2014;9(1):12–20.PubMedCrossRef Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol. 2014;9(1):12–20.PubMedCrossRef
8.
go back to reference Li SY, Chen JY, Yang WC, Chuang CL. Acute kidney injury network classification predicts in-hospital and long-term mortality in patients undergoing elective coronary artery bypass grafting surgery. Eur J Cardiothorac Surg. 2011;39(3):323–8.PubMedCrossRef Li SY, Chen JY, Yang WC, Chuang CL. Acute kidney injury network classification predicts in-hospital and long-term mortality in patients undergoing elective coronary artery bypass grafting surgery. Eur J Cardiothorac Surg. 2011;39(3):323–8.PubMedCrossRef
9.
go back to reference Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748–57.PubMedPubMedCentralCrossRef Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748–57.PubMedPubMedCentralCrossRef
10.
go back to reference Odutayo A, Wong CX, Farkouh M, Altman DG, Hopewell S, Emdin CA, Hunn BH. AKI and long-term risk for cardiovascular events and mortality. J Am Soc Nephrol. 2017;28(1):377–87.PubMedCrossRef Odutayo A, Wong CX, Farkouh M, Altman DG, Hopewell S, Emdin CA, Hunn BH. AKI and long-term risk for cardiovascular events and mortality. J Am Soc Nephrol. 2017;28(1):377–87.PubMedCrossRef
11.
go back to reference Ostermann M. Diagnosis of acute kidney injury: kidney disease improving global outcomes criteria and beyond. Curr Opin Crit Care. 2014;20(6):581–7.PubMedCrossRef Ostermann M. Diagnosis of acute kidney injury: kidney disease improving global outcomes criteria and beyond. Curr Opin Crit Care. 2014;20(6):581–7.PubMedCrossRef
12.
go back to reference Vijayan A, Faubel S, Askenazi DJ, Cerda J, Fissell WH, Heung M, Humphreys BD, Koyner JL, Liu KD, Mour G, et al. Clinical use of the urine biomarker [TIMP-2] x [IGFBP7] for acute kidney injury risk assessment. Am J Kidney Dis. 2016;68(1):19–28.PubMedPubMedCentralCrossRef Vijayan A, Faubel S, Askenazi DJ, Cerda J, Fissell WH, Heung M, Humphreys BD, Koyner JL, Liu KD, Mour G, et al. Clinical use of the urine biomarker [TIMP-2] x [IGFBP7] for acute kidney injury risk assessment. Am J Kidney Dis. 2016;68(1):19–28.PubMedPubMedCentralCrossRef
13.
go back to reference Coca SG, Garg AX, Thiessen-Philbrook H, Koyner JL, Patel UD, Krumholz HM, Shlipak MG, Parikh CR, Consortium T-A. Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J Am Soc Nephrol. 2014;25(5):1063–71.PubMedCrossRef Coca SG, Garg AX, Thiessen-Philbrook H, Koyner JL, Patel UD, Krumholz HM, Shlipak MG, Parikh CR, Consortium T-A. Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J Am Soc Nephrol. 2014;25(5):1063–71.PubMedCrossRef
14.
go back to reference Alge JL, Arthur JM. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol. 2015;10(1):147–55.PubMedCrossRef Alge JL, Arthur JM. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol. 2015;10(1):147–55.PubMedCrossRef
15.
go back to reference Parikh CR, Puthumana J, Shlipak MG, Koyner JL, Thiessen-Philbrook H, McArthur E, Kerr K, Kavsak P, Whitlock RP, Garg AX, et al. Relationship of kidney injury biomarkers with long-term cardiovascular outcomes after cardiac surgery. J Am Soc Nephrol. 2017;28(12):3699–707.PubMedPubMedCentralCrossRef Parikh CR, Puthumana J, Shlipak MG, Koyner JL, Thiessen-Philbrook H, McArthur E, Kerr K, Kavsak P, Whitlock RP, Garg AX, et al. Relationship of kidney injury biomarkers with long-term cardiovascular outcomes after cardiac surgery. J Am Soc Nephrol. 2017;28(12):3699–707.PubMedPubMedCentralCrossRef
16.
go back to reference Wang W, Pan Y, Tang X, Hao G, Xie Y, Ma S, Luo J, Guo D, Ding F. Serum prealbumin and its changes over time are associated with mortality in acute kidney injury. Sci Rep. 2017;7:41493.PubMedPubMedCentralCrossRef Wang W, Pan Y, Tang X, Hao G, Xie Y, Ma S, Luo J, Guo D, Ding F. Serum prealbumin and its changes over time are associated with mortality in acute kidney injury. Sci Rep. 2017;7:41493.PubMedPubMedCentralCrossRef
17.
go back to reference Liabeuf S, Cheddani L, Massy ZA. Uremic toxins and clinical outcomes: the impact of kidney transplantation. Toxins (Basel). 2018;10(6).PubMedCentralCrossRef Liabeuf S, Cheddani L, Massy ZA. Uremic toxins and clinical outcomes: the impact of kidney transplantation. Toxins (Basel). 2018;10(6).PubMedCentralCrossRef
18.
go back to reference Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci. 2010;72(1–2):1–11.PubMed Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci. 2010;72(1–2):1–11.PubMed
19.
go back to reference Shen WC, Liang CJ, Huang TM, Liu CW, Wang SH, Young GH, Tsai JS, Tseng YC, Peng YS, Wu VC, et al. Indoxyl sulfate enhances IL-1beta-induced E-selectin expression in endothelial cells in acute kidney injury by the ROS/MAPKs/NFkappaB/AP-1 pathway. Arch Toxicol. 2016;90(11):2779–92.PubMedCrossRef Shen WC, Liang CJ, Huang TM, Liu CW, Wang SH, Young GH, Tsai JS, Tseng YC, Peng YS, Wu VC, et al. Indoxyl sulfate enhances IL-1beta-induced E-selectin expression in endothelial cells in acute kidney injury by the ROS/MAPKs/NFkappaB/AP-1 pathway. Arch Toxicol. 2016;90(11):2779–92.PubMedCrossRef
20.
go back to reference Wu VC, Young GH, Huang PH, Lo SC, Wang KC, Sun CY, Liang CJ, Huang TM, Chen JH, Chang FC, et al. In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin. Angiogenesis. 2013;16(3):609–24.PubMedCrossRef Wu VC, Young GH, Huang PH, Lo SC, Wang KC, Sun CY, Liang CJ, Huang TM, Chen JH, Chang FC, et al. In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin. Angiogenesis. 2013;16(3):609–24.PubMedCrossRef
21.
go back to reference Yang CY, Tarng DC. Diet, gut microbiome and indoxyl sulphate in chronic kidney disease patients. Nephrology (Carlton, Vic). 2018;23(Suppl 4):16–20.CrossRef Yang CY, Tarng DC. Diet, gut microbiome and indoxyl sulphate in chronic kidney disease patients. Nephrology (Carlton, Vic). 2018;23(Suppl 4):16–20.CrossRef
22.
go back to reference Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. Jama. 1996;275(19):1489–94.PubMedCrossRef Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. Jama. 1996;275(19):1489–94.PubMedCrossRef
23.
go back to reference Rhee H, Jang KS, Park JM, Kang JS, Hwang NK, Kim IY, Song SH, Seong EY, Lee DW, Lee SB, et al. Short- and long-term mortality rates of elderly acute kidney injury patients who underwent continuous renal replacement therapy. PLoS One. 2016;11(11):e0167067.PubMedPubMedCentralCrossRef Rhee H, Jang KS, Park JM, Kang JS, Hwang NK, Kim IY, Song SH, Seong EY, Lee DW, Lee SB, et al. Short- and long-term mortality rates of elderly acute kidney injury patients who underwent continuous renal replacement therapy. PLoS One. 2016;11(11):e0167067.PubMedPubMedCentralCrossRef
24.
go back to reference O'Sullivan ED, Doyle A. The clinical utility of kinetic glomerular filtration rate. Clin Kidney J. 2017;10(2):202–8.PubMed O'Sullivan ED, Doyle A. The clinical utility of kinetic glomerular filtration rate. Clin Kidney J. 2017;10(2):202–8.PubMed
25.
go back to reference Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol. 2017;18(1):35–017-0457-0451.PubMedPubMedCentralCrossRef Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol. 2017;18(1):35–017-0457-0451.PubMedPubMedCentralCrossRef
26.
go back to reference Barisione C, Ghigliotti G, Canepa M, Balbi M, Brunelli C, Ameri P. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Curr Drug Targets. 2015;16(4):366–72.PubMedCrossRef Barisione C, Ghigliotti G, Canepa M, Balbi M, Brunelli C, Ameri P. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Curr Drug Targets. 2015;16(4):366–72.PubMedCrossRef
27.
go back to reference Lee CT, Hsu CY, Tain YL, Ng HY, Cheng BC, Yang CC, Wu CH, Chiou TT, Lee YT, Liao SC. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients. Blood Purif. 2014;37(1):76–83.PubMedCrossRef Lee CT, Hsu CY, Tain YL, Ng HY, Cheng BC, Yang CC, Wu CH, Chiou TT, Lee YT, Liao SC. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients. Blood Purif. 2014;37(1):76–83.PubMedCrossRef
28.
go back to reference Shafi T, Sirich TL, Meyer TW, Hostetter TH, Plummer NS, Hwang S, Melamed ML, Banerjee T, Coresh J, Powe NR. Results of the HEMO study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. Kidney Int. 2017;92(6):1484–92.PubMedPubMedCentralCrossRef Shafi T, Sirich TL, Meyer TW, Hostetter TH, Plummer NS, Hwang S, Melamed ML, Banerjee T, Coresh J, Powe NR. Results of the HEMO study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. Kidney Int. 2017;92(6):1484–92.PubMedPubMedCentralCrossRef
29.
go back to reference Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, Yoon SA, Han SY, Chang JH, Park SK, et al. A randomized, controlled trial of Oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol. 2016;11(4):559–67.PubMedPubMedCentralCrossRef Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, Yoon SA, Han SY, Chang JH, Park SK, et al. A randomized, controlled trial of Oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol. 2016;11(4):559–67.PubMedPubMedCentralCrossRef
Metadata
Title
Indoxyl sulfate is associated with mortality after AKI – more evidence needed!
Authors
Steven Menez
Mohamad Hanouneh
Tariq Shafi
Bernard G. Jaar
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1465-0

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.